[go: up one dir, main page]

MX2007010752A - Usos oftalmicos de moduladores de receptor s1p. - Google Patents

Usos oftalmicos de moduladores de receptor s1p.

Info

Publication number
MX2007010752A
MX2007010752A MX2007010752A MX2007010752A MX2007010752A MX 2007010752 A MX2007010752 A MX 2007010752A MX 2007010752 A MX2007010752 A MX 2007010752A MX 2007010752 A MX2007010752 A MX 2007010752A MX 2007010752 A MX2007010752 A MX 2007010752A
Authority
MX
Mexico
Prior art keywords
receptor modulators
ophthalmic uses
ophthalmic
medicament
manufacture
Prior art date
Application number
MX2007010752A
Other languages
English (en)
Inventor
George N Lambrou
Elisabeth Jeanne Latour
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2007010752A publication Critical patent/MX2007010752A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion pertenece al uso de un agonista del receptor S1P en la elaboracion de un medicamento para el tratamiento de un trastorno ocular.
MX2007010752A 2005-03-04 2006-03-02 Usos oftalmicos de moduladores de receptor s1p. MX2007010752A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0504544.8A GB0504544D0 (en) 2005-03-04 2005-03-04 Organic compounds
PCT/EP2006/001905 WO2006094705A1 (en) 2005-03-04 2006-03-02 Ophthalmic uses of s1p receptor modulators

Publications (1)

Publication Number Publication Date
MX2007010752A true MX2007010752A (es) 2007-09-12

Family

ID=34451836

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007010752A MX2007010752A (es) 2005-03-04 2006-03-02 Usos oftalmicos de moduladores de receptor s1p.

Country Status (12)

Country Link
US (3) US20080207739A1 (es)
EP (2) EP2216019A3 (es)
JP (2) JP2008531632A (es)
KR (1) KR20070108216A (es)
CN (1) CN101132784A (es)
AU (2) AU2006222266A1 (es)
BR (1) BRPI0609258A2 (es)
CA (1) CA2598527A1 (es)
GB (1) GB0504544D0 (es)
MX (1) MX2007010752A (es)
RU (2) RU2497513C2 (es)
WO (1) WO2006094705A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2820510A1 (en) * 2005-09-09 2007-03-15 Novartis Ag Treatment of autoimmune diseases
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
KR20090057399A (ko) * 2006-09-26 2009-06-05 노파르티스 아게 Ｓ１ｐ 조정제를 포함하는 제약 조성물
KR20100021430A (ko) 2007-05-04 2010-02-24 노파르티스 아게 Ｓ1ｐ 수용체 조절제의 용도
WO2008154470A1 (en) * 2007-06-08 2008-12-18 University Of Connecticut Nhibitor of the receptor activity of the s1p2 receptor for inhibiting pathological angiogenesis in the eye
EP3733161A1 (en) 2007-10-12 2020-11-04 Novartis AG Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
KR20130066630A (ko) * 2010-05-06 2013-06-20 노파르티스 아게 자가면역 질환의 치료
UA114283C2 (uk) 2011-01-07 2017-05-25 Новартіс Аг Композиції імуносупресантів
CN104771385A (zh) * 2014-01-13 2015-07-15 复旦大学附属华山医院 Fty720在制备治疗干眼症药物中的用途
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
CN105395530A (zh) * 2015-11-27 2016-03-16 天津医科大学总医院 芬戈莫德的新用途
BR112020015567A2 (pt) * 2018-02-02 2021-02-02 Kyoto University medicamento para prevenir ou tratar doença oftálmica associada com neovascularização intraocular e/ou permeabilidade vascular intraocular realçadas
IL298996A (en) * 2020-06-11 2023-02-01 Univ Columbia Methods and preparations for the prevention and treatment of myopia (myopia) with pingolimod, a sphingosine-1-phosphate receptor modulator, and their derivatives

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
EP0627406B1 (en) * 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
SG64372A1 (en) 1993-12-17 1999-04-27 Novartis Ag Rapamycin derivatives
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
AU712193B2 (en) 1995-06-09 1999-10-28 Novartis Ag Rapamycin derivatives
IL121625A (en) * 1995-12-28 2001-09-13 Welfide Corp Preparation containing 2 - amino - 2 - (-2 (-4-octylphenyl) ethyl) propane - 1, 3, - dial for local topical use
RU2198162C2 (ru) 1997-04-04 2003-02-10 Мицубиси Фарма Корпорейшн Производное 2-аминопропан-1,3-диола, его фармацевтическое применение и промежуточные продукты для их синтеза
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
BR0112484A (pt) 2000-07-13 2003-09-23 Sankyo Co Composto ou um seu sal, éster ou outro derivado farmacologicamente aceitável, composição farmacêutica, uso de um composto ou de um seu sal, éster ou outro derivado farmacologicamente aceitável, e, processo para a preparação do mesmo
AU8533101A (en) * 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
WO2002076995A2 (en) 2001-03-26 2002-10-03 Novartis Ag 2-amino-propanol derivatives
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
AU2002332289B2 (en) 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
WO2003029184A1 (en) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
JP4709488B2 (ja) 2002-01-18 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
AU2003216054B2 (en) * 2002-01-18 2007-01-04 Merck & Co., Inc. Selective S1P1/Edg1 receptor agonists
AU2003207567B2 (en) 2002-01-18 2008-01-24 Merck Sharp & Dohme Corp. Edg receptor agonists
US7482491B2 (en) 2002-09-19 2009-01-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
EP1622866B1 (en) * 2003-04-30 2012-07-25 Novartis AG Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
AU2004251146A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
GB0313612D0 (en) * 2003-06-12 2003-07-16 Novartis Ag Organic compounds
WO2005014525A2 (en) * 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
WO2006056823A1 (en) * 2004-11-26 2006-06-01 Novagali Pharma Sa Modulating retinal pigmented epithelium permeation by inhibiting or activating vegfr-1

Also Published As

Publication number Publication date
CN101132784A (zh) 2008-02-27
US20130065954A1 (en) 2013-03-14
BRPI0609258A2 (pt) 2010-03-09
AU2010202185A1 (en) 2010-06-17
WO2006094705A1 (en) 2006-09-14
AU2006222266A1 (en) 2006-09-14
RU2007136602A (ru) 2009-04-10
EP2216019A3 (en) 2010-11-17
RU2011115499A (ru) 2012-10-27
US20110313033A1 (en) 2011-12-22
KR20070108216A (ko) 2007-11-08
AU2010202185B2 (en) 2012-06-14
EP2216019A2 (en) 2010-08-11
CA2598527A1 (en) 2006-09-14
GB0504544D0 (en) 2005-04-13
RU2497513C2 (ru) 2013-11-10
US20080207739A1 (en) 2008-08-28
JP2008531632A (ja) 2008-08-14
JP2013063991A (ja) 2013-04-11
EP1861081A1 (en) 2007-12-05

Similar Documents

Publication Publication Date Title
TN2009000381A1 (en) C5 antigens and uses thereof
MX2009007394A (es) Tapones puntuales y metodos de entrega de agentes terapeuticos.
MX2009013989A (es) Terapia en combinacion para depresion.
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
EA201001785A1 (ru) Модуляторы рецепторов сфингозин-1-фосфата
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
MX2007010752A (es) Usos oftalmicos de moduladores de receptor s1p.
CA2711696C (en) Therapeutic compositions for treatment of ocular inflammatory disorders
GB2467666A (en) Wearable towel
EA019970B8 (ru) Производные имидазолидиндиона
PL2049132T3 (pl) Nowe środki do leczenia zaburzeń związanych z osłabionym neuroprzekaźnictwem
ME01532B (me) Jedinjenja
MY171920A (en) Prevention and treatment of ocular conditions
WO2010068281A3 (en) Contact lens drug delivery device
LT2959894T (lt) S1p receptoriaus moduliatoriai, skirti išsėtinės sklerozės gydymui
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
IL201479A (en) Use of tapentadol for the preparation of pain medication
MX2009009415A (es) Compuestos de tetrahidroisoquinolina como moduladores del receptor h3 de la histamina.
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
MX2009012645A (es) Formulaciones y metodos para tratar el ojo seco.
TW200742884A (en) Multifocal contact lens designs utilizing pupil apodization
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
ZA200802010B (en) Pyrimidine compounds as serotonin receptor modulators
MY146506A (en) Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
BRPI0917440A2 (pt) composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho

Legal Events

Date Code Title Description
FA Abandonment or withdrawal